摘要
[目的]探讨Neo-Bioscore评分系统对比临床分期系统、病理分期系统以及CPS+EG评分系统在乳腺癌新辅助化疗预后评估的价值。[方法]收集2010年1月至2017年6月乳腺癌新辅助化疗198例患者资料,随访时间为期5年,分别通过4个不同的分期系统进行预后评估,计算5年总体生存率。[结果]全组198例患者5年总生存率为72%;不同病理分期之间生存情况存在较多的交叉(P>0.05),而Neo-Bioscore评分系统变化区间最大(P<0.05)。Neo-Bioscore高分值(>3分)与低分值组(≤3分)组生存率比较差异有统计学意义(χ~2=17.353,P<0.05)。[结论] Neo-Bioscore分期系统显示出较好的预后评估价值,能更全面地预测乳腺癌新辅助化疗患者的预后。
[Objective]To assess the application of Neo-Bioscore system in evaluating prognosis of breast cancer patients receiving neoadjuvant chemotherapy.[Methods]One hundred and ninety eight patients with breast cancer received neoadjuvant chemotherapy in Renmin Hospital of Wuhan University from January 2010 to June 2017.Patients were followed-up for 5 years,and the 5-year overall survival rate(OS)was calculated.The prognosis of patients was evaluated with clinical staging system,pathological staging system,CPS+EG scoring system and Neo-Bioscore system.[Results]The 5-year overall survival rate was 72%in these patients.Kaplan-Meier survival curve analysis showed that the Neo-Bioscore system had better prognostic stratification than other three systems.The overall survival was significant difference in high Neo-Bioscore group(>3)and low score group(≤3)(χ~2=17.353,P<0.05).[Conclusion]Neo-Bioscore system shows a better prognostic value to predict the survival of breast cancer patients undergoing neoadjuvant chemotherapy.
作者
焦武
姚峰
汪雯洁
JIAO Wu;YAO Feng;WANG Wen-jie(Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《肿瘤学杂志》
CAS
2019年第5期432-435,共4页
Journal of Chinese Oncology
基金
湖北省计生委科研项目(JS-2011019)
